# Eternygen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eternygen

- Industry: Biotechnology
- Headquarters: Berlin, Germany
- Website: www.eternygen.com
- Total disclosed funding: $14M
- Latest round: Series A (Oct 26, 2020)
- Investors on record: 4

## About

Founded in 2012 and based in Berlin, Germany, Eternygen GmbH is a biotech company that focused on the research and development of NaCT inhibitors for the treatment of dietary-related metabolic diseases.

## Funding rounds

- Series A, Oct 26, 2020, $5.9M — IBB Ventures, Evotec SE, Epidarex Capital
- Series A, Dec 8, 2016, $8.4M — IBB Ventures, Evotec SE, Epidarex Capital, Alertin GmbH & Co. kg
- Seed, Oct 1, 2012 — IBB Ventures

## Investors

- IBB Ventures (https://capitalatlas.ai/funds/ibb-ventures) — Seed, Series A
- Evotec SE — Series A
- Epidarex Capital (https://capitalatlas.ai/funds/epidarex-capital) — Series A
- Alertin GmbH & Co. kg — Series A